TransMedics Group Inc vs Tapestry, Inc. — how do they compare? TransMedics Group Inc trades at $80.9 (market cap $2.74B), while Tapestry, Inc. trades at $115.14 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 8.4× TransMedics Group Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Tapestry, Inc. for 70 Days on average.
| TMDX | TPR | |
|---|---|---|
Market Cap | $2.74B | $23.09B |
Volume | 949,331 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $150.42 | $164.78 |
52-Week Low | $61.99 | $98.81 |
Typical Hold Time | 24 Days | 70 Days |
Enterprise Value | $3.13B | $25.89B |
Dividend Yield | — | 1.6% |
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
TPR trades at $113.39, down 2.86% today, with a bearish technical signal from moving averages. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly to $183M from $816M in 2024. Recent earnings beats and a 73% analyst buy rating support optimism, while technical indicators show resistance near $114-116. The stock trades at a P/E of 15.93, below the consensus price target of $174.64.
Outlook remains positive based on analyst consensus and earnings momentum, but risks include Kate Spade execution challenges, tariff pressures, and volatile cash flows. The current price offers potential upside to targets, though technical weakness near-term requires monitoring support at $111-113. Revenue growth to $8B in 2026 with margin expansion could drive valuation if execution improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →